IRFI 165
Document Actions
|
|
IRFI 165 |
|
|
IRFI 165 |
|
|
N-cyclopentyl-1-methylimidazo[1,2-a]quinoxalin-4-amine |
|
|
N7 other cns drugs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adenosine A1 receptor antagonist |
|
|
The compound is undergoing preclinical evaluation as a potential CNS-selective psychotropic agent. It displayed A1-binding affinity at 10-8M and did not significantly affect radioligand binding to 30 receptor classes. In Porsolt's behavioural models in mice and rats IRFI 165 effectively reduced the time spent immobile from the doses of 0.01-0.1 mg/kg i.p. Unlike most xanthine A1-antagonists, the anti-immobility effect of IRFI 165 is strongly reversed by co-administration of diazepam, similarly to the tricyclic antidepressants desipramine and imipramine. The Porsolt activity of IRFI 165 was seen both after acute and repeated administration and it seems to be independent of methylxanthine-like stimulant activity. IRFI 165 showed no diuretic or natriuretic effects at the doses active on the Porsolt's tests. |
|
|
Pre-clinical |
|
|
Italy |
|
|
|
|
|
|
|
|
license |
|
|
dr. Stefano Ceccarelli Regulatory Affairs & Licensing Manager Biomedica Foscama SpA via Morolense, 87 03013 Ferentino (FR), Italy tel. +39 0775 8021 fax: +39 0775 223363 |
|
|
http://biomedicafoscama.com |
|
|
There are currently no items in this folder.
Last modified
2005-09-08 20:32
Contact this User
|
|
